China-based Sciwind Biosciences has entered into a strategic commercialisation agreement with Pfizer China for ecnoglutide, a next-generation cAMP-biased GLP-1 receptor agonist. Under the agreement, Pfizer obtains exclusive commercialisation rights for the product in Mainland China, while Sciwind remains the marketing authorisation holder (MAH) responsible for R&D, registration, production, and supply. Sciwind is eligible to receive up to USD 495 million in payments, including an upfront fee and milestone payments tied to registration and sales.

Ecnoglutide, approved in China for type 2 diabetes (T2D) in January 2026, is a self-developed candidate that has demonstrated promising weight loss and glycaemic control in late-stage studies. A Phase III trial for T2D showed superior HbA1c reduction compared to dulaglutide. A separate Phase III weight management study reported an average 15.4% weight loss at 48 weeks. The partnership aims to accelerate the drug's market access in China's growing metabolic disease sector.

According to PharmCube's NextBiopharm® database, ecnoglutide was originally developed by Kawin Technology, with Sciwind later granting partial rights to inno.N. Click here to request a free trial for NextBiopharm®.